Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:CCDC6-PDGFRB (FusionGDB2 ID:HG8030TG5159)

Fusion Gene Summary for CCDC6-PDGFRB

Fusion gene summary

Fusion gene information	Fusion gene name: CCDC6-PDGFRB
	Fusion gene ID: hg8030tg5159
		Hgene	Tgene
	Gene symbol	CCDC6	PDGFRB
	Gene ID	8030	5159
	Gene name	coiled-coil domain containing 6	platelet derived growth factor receptor beta
	Synonyms	D10S170\|H4\|PTC\|TPC\|TST1	CD140B\|IBGC4\|IMF1\|JTK12\|KOGS\|PDGFR\|PDGFR-1\|PDGFR1\|PENTT
	Cytomap	('CCDC6')('PDGFRB') 10q21.2	5q32
	Type of gene	protein-coding	protein-coding
	Description	coiled-coil domain-containing protein 6papillary thyroid carcinoma-encoded protein	platelet-derived growth factor receptor betaActivated tyrosine kinase PDGFRBCD140 antigen-like family member BNDEL1-PDGFRBPDGF-R-betaPDGFR-betabeta-type platelet-derived growth factor receptorplatelet-derived growth factor receptor 1platelet-deriv
	Modification date	20200327	20200329
	UniProtAcc	Q16204	P09619
	Ensembl transtripts involved in fusion gene	ENST00000263102,
Fusion gene scores	* DoF score	15 X 22 X 10=3300	28 X 26 X 6=4368
	# samples	38	15
	** MAII score	log2(38/3300*10)=-3.11839470080223 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(15/4368*10)=-4.86393845042397 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: CCDC6 [Title/Abstract] AND PDGFRB [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	CCDC6(61564178)-PDGFRB(149506178), # samples:1
Anticipated loss of major functional domain due to fusion event.	CCDC6-PDGFRB seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CCDC6-PDGFRB seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CCDC6-PDGFRB seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CCDC6-PDGFRB seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	PDGFRB	GO:0007165	signal transduction	10821867
Tgene	PDGFRB	GO:0010863	positive regulation of phospholipase C activity	1653029
Tgene	PDGFRB	GO:0018108	peptidyl-tyrosine phosphorylation	1653029\|2536956\|2850496
Tgene	PDGFRB	GO:0030335	positive regulation of cell migration	17470632
Tgene	PDGFRB	GO:0032516	positive regulation of phosphoprotein phosphatase activity	7691811
Tgene	PDGFRB	GO:0038091	positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	17470632
Tgene	PDGFRB	GO:0043552	positive regulation of phosphatidylinositol 3-kinase activity	1314164
Tgene	PDGFRB	GO:0046777	protein autophosphorylation	1314164\|2536956\|2850496
Tgene	PDGFRB	GO:0048008	platelet-derived growth factor receptor signaling pathway	1314164\|2536956
Tgene	PDGFRB	GO:0060326	cell chemotaxis	2554309\|17991872

Fusion gene breakpoints across CCDC6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across PDGFRB (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerKB3	.	.	CCDC6	chr10	61564177	-	PDGFRB	chr5	149506177	-

Top

Fusion Gene ORF analysis for CCDC6-PDGFRB

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
5CDS-intron	ENST00000263102	ENST00000523456	CCDC6	chr10	61564177	-	PDGFRB	chr5	149506177	-
In-frame	ENST00000263102	ENST00000261799	CCDC6	chr10	61564177	-	PDGFRB	chr5	149506177	-

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000263102

CCDC6

chr10

61564177

ENST00000261799

PDGFRB

chr5

149506177

5005

1337

109

3078

989

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000263102	ENST00000261799	CCDC6	chr10	61564178	-	PDGFRB	chr5	149506178	-	0.004267533	0.9957325

Top

Fusion Genomic Features for CCDC6-PDGFRB

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Top

Fusion Protein Features for CCDC6-PDGFRB

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:61564178/chr5:149506178)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
CCDC6 Q16204	PDGFRB P09619
	FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. {ECO:0000269\|PubMed:11297552, ECO:0000269\|PubMed:11331881, ECO:0000269\|PubMed:1314164, ECO:0000269\|PubMed:1396585, ECO:0000269\|PubMed:1653029, ECO:0000269\|PubMed:1709159, ECO:0000269\|PubMed:1846866, ECO:0000269\|PubMed:20494825, ECO:0000269\|PubMed:20529858, ECO:0000269\|PubMed:21098708, ECO:0000269\|PubMed:21679854, ECO:0000269\|PubMed:21733313, ECO:0000269\|PubMed:2554309, ECO:0000269\|PubMed:26599395, ECO:0000269\|PubMed:2835772, ECO:0000269\|PubMed:2850496, ECO:0000269\|PubMed:7685273, ECO:0000269\|PubMed:7691811, ECO:0000269\|PubMed:7692233, ECO:0000269\|PubMed:8195171}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

253_332

368

475.0

Coiled coil

Ontology_term=ECO:0000255

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

53_237

368

475.0

Coiled coil

Ontology_term=ECO:0000255

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

17_20

368

475.0

Compositional bias

Note=Poly-Ser

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

32_44

368

475.0

Compositional bias

Note=Poly-Gly

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

106_235

368

475.0

Region

Note=5 X 29 AA tandem repeats

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

106_134

368

475.0

Repeat

Note=1

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

135_163

368

475.0

Repeat

Note=2

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

164_192

368

475.0

Repeat

Note=3

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

193_206

368

475.0

Repeat

Note=4%3B approximate

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

207_235

368

475.0

Repeat

Note=5

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

600_962

526

1107.0

Domain

Protein kinase

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

606_614

526

1107.0

Nucleotide binding

ATP

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

554_1106

526

1107.0

Topological domain

Cytoplasmic

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

533_553

526

1107.0

Transmembrane

Helical

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

440_448

368

475.0

Compositional bias

Note=Poly-Pro

Hgene

CCDC6

chr10:61564178

chr5:149506178

ENST00000263102

442_451

368

475.0

Motif

SH3-binding

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

129_210

526

1107.0

Domain

Note=Ig-like C2-type 2

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

214_309

526

1107.0

Domain

Note=Ig-like C2-type 3

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

331_403

526

1107.0

Domain

Note=Ig-like C2-type 4

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

33_120

526

1107.0

Domain

Note=Ig-like C2-type 1

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

416_524

526

1107.0

Domain

Note=Ig-like C2-type 5

Tgene

PDGFRB

chr10:61564178

chr5:149506178

ENST00000261799

33_532

526

1107.0

Topological domain

Extracellular

Top

Fusion Gene Sequence for CCDC6-PDGFRB

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>13894_13894_1_CCDC6-PDGFRB_CCDC6_chr10_61564177_ENST00000263102_PDGFRB_chr5_149506177_ENST00000261799_length(transcript)=5005nt_BP=1337nt
AGTGCAATACTGCCCAAGCCCGGGCGGGGTCTCTGTTCTCTGGCAGAGGAGGTCCCTTGGCAGCGGGAAGCGCCCTCTCTTTCTCTCGCC
GCCGCTCCGAGTCTGCGCCCTGGTGCCAGGCGCTCAGCTCGGCGCTCCCCTGTGCTCGCCCGGCGCCCACTCATTCGCAGCCCGGCCTTC
GTCGCCGCCGCCTCCCTGCTGCTCCTCCTCCTTTCCCCAGCCCGCCGCGGCCATGGCGGACAGCGCCAGCGAGAGCGACACGGACGGGGC
GGGGGGCAACAGCAGCAGCTCGGCCGCCATGCAGTCGTCCTGCTCGTCGACCTCGGGCGGCGGCGGTGGCGGCGGGGGAGGCGGCGGCGG
TGGGAAGTCGGGGGGCATTGTCATCTCGCCGTTCCGCCTGGAGGAGCTCACCAACCGCCTGGCCTCGCTGCAGCAAGAGAACAAGGTGCT
GAAGATAGAGCTGGAGACCTACAAACTGAAGTGCAAGGCACTGCAGGAGGAGAACCGCGACCTGCGCAAAGCCAGCGTGACCATCCAAGC
CAGGGCTGAGCAGGAAGAAGAATTCATTAGTAACACTTTATTCAAGAAAATTCAGGCTTTGCAGAAGGAGAAAGAAACCCTTGCTGTAAA
TTATGAGAAAGAAGAAGAATTCCTCACTAATGAGCTCTCCAGAAAATTGATGCAGTTGCAGCATGAGAAAGCCGAACTAGAACAGCATCT
TGAACAAGAGCAGGAATTTCAGGTCAACAAACTGATGAAGAAAATTAAAAAACTGGAGAATGACACCATTTCTAAGCAACTTACATTAGA
ACAGTTGAGACGGGAGAAGATTGACCTTGAAAATACATTGGAACAAGAACAAGAAGCACTAGTTAATCGCCTCTGGAAAAGGATGGATAA
GCTTGAAGCTGAAAAGCGAATCCTGCAGGAAAAATTAGACCAGCCCGTCTCTGCTCCACCATCGCCTAGAGATATCTCCATGGAGATTGA
TTCTCCAGAAAATATGATGCGTCACATCAGGTTTTTAAAGAATGAAGTGGAACGGCTGAAGAAGCAACTGAGAGCTGCTCAGTTACAGCA
TTCAGAGAAAATGGCACAGTATCTGGAGGAGGAACGTCACATGAGAGAAGAGAACTTGAGGCTCCAGAGGAAGCTGCAGAGGGAGATGGA
GAGAAGAGAAGCCCTCTGTCGACAGCTCTCCGAGAGTGAGTCCAGCTTAGAAATGGACGACGAAAGGTATTTTAATGAGATGTCTGCACA
AGGATTAAGACCTCGCACTGTGTCCAGCCCGATCCCTTACACACCTTCTCCGAGTTCAAGCAGGCCTATATCACCTGCCTTGCCCTTTAA
GGTGGTGGTGATCTCAGCCATCCTGGCCCTGGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCACG
TTACGAGATCCGATGGAAGGTGATTGAGTCTGTGAGCTCTGACGGCCATGAGTACATCTACGTGGACCCCATGCAGCTGCCCTATGACTC
CACGTGGGAGCTGCCGCGGGACCAGCTTGTGCTGGGACGCACCCTCGGCTCTGGGGCCTTTGGGCAGGTGGTGGAGGCCACGGCTCATGG
CCTGAGCCATTCTCAGGCCACGATGAAAGTGGCCGTCAAGATGCTTAAATCCACAGCCCGCAGCAGTGAGAAGCAAGCCCTTATGTCGGA
GCTGAAGATCATGAGTCACCTTGGGCCCCACCTGAACGTGGTCAACCTGTTGGGGGCCTGCACCAAAGGAGGACCCATCTATATCATCAC
TGAGTACTGCCGCTACGGAGACCTGGTGGACTACCTGCACCGCAACAAACACACCTTCCTGCAGCACCACTCCGACAAGCGCCGCCCGCC
CAGCGCGGAGCTCTACAGCAATGCTCTGCCCGTTGGGCTCCCCCTGCCCAGCCATGTGTCCTTGACCGGGGAGAGCGACGGTGGCTACAT
GGACATGAGCAAGGACGAGTCGGTGGACTATGTGCCCATGCTGGACATGAAAGGAGACGTCAAATATGCAGACATCGAGTCCTCCAACTA
CATGGCCCCTTACGATAACTACGTTCCCTCTGCCCCTGAGAGGACCTGCCGAGCAACTTTGATCAACGAGTCTCCAGTGCTAAGCTACAT
GGACCTCGTGGGCTTCAGCTACCAGGTGGCCAATGGCATGGAGTTTCTGGCCTCCAAGAACTGCGTCCACAGAGACCTGGCGGCTAGGAA
CGTGCTCATCTGTGAAGGCAAGCTGGTCAAGATCTGTGACTTTGGCCTGGCTCGAGACATCATGCGGGACTCGAATTACATCTCCAAAGG
CAGCACCTTTTTGCCTTTAAAGTGGATGGCTCCGGAGAGCATCTTCAACAGCCTCTACACCACCCTGAGCGACGTGTGGTCCTTCGGGAT
CCTGCTCTGGGAGATCTTCACCTTGGGTGGCACCCCTTACCCAGAGCTGCCCATGAACGAGCAGTTCTACAATGCCATCAAACGGGGTTA
CCGCATGGCCCAGCCTGCCCATGCCTCCGACGAGATCTATGAGATCATGCAGAAGTGCTGGGAAGAGAAGTTTGAGATTCGGCCCCCCTT
CTCCCAGCTGGTGCTGCTTCTCGAGAGACTGTTGGGCGAAGGTTACAAAAAGAAGTACCAGCAGGTGGATGAGGAGTTTCTGAGGAGTGA
CCACCCAGCCATCCTTCGGTCCCAGGCCCGCTTGCCTGGGTTCCATGGCCTCCGATCTCCCCTGGACACCAGCTCCGTCCTCTATACTGC
CGTGCAGCCCAATGAGGGTGACAACGACTATATCATCCCCCTGCCTGACCCCAAACCCGAGGTTGCTGACGAGGGCCCACTGGAGGGTTC
CCCCAGCCTAGCCAGCTCCACCCTGAATGAAGTCAACACCTCCTCAACCATCTCCTGTGACAGCCCCCTGGAGCCCCAGGACGAACCAGA
GCCAGAGCCCCAGCTTGAGCTCCAGGTGGAGCCGGAGCCAGAGCTGGAACAGTTGCCGGATTCGGGGTGCCCTGCGCCTCGGGCGGAAGC
AGAGGATAGCTTCCTGTAGGGGGCTGGCCCCTACCCTGCCCTGCCTGAAGCTCCCCCCCTGCCAGCACCCAGCATCTCCTGGCCTGGCCT
GACCGGGCTTCCTGTCAGCCAGGCTGCCCTTATCAGCTGTCCCCTTCTGGAAGCTTTCTGCTCCTGACGTGTTGTGCCCCAAACCCTGGG
GCTGGCTTAGGAGGCAAGAAAACTGCAGGGGCCGTGACCAGCCCTCTGCCTCCAGGGAGGCCAACTGACTCTGAGCCAGGGTTCCCCCAG
GGAACTCAGTTTTCCCATATGTAAAATGGGAAAGTTAGGCTTGATGACCCAGAATCTAGGATTCTCTCCCTGGCTGACAGGTGGGGAGAC
CGAATCCCTCCCTGGGAAGATTCTTGGAGTTACTGAGGTGGTAAATTAACTTTTTTCTGTTCAGCCAGCTACCCCTCAAGGAATCATAGC
TCTCTCCTCGCACTTTTATCCACCCAGGAGCTAGGGAAGAGACCCTAGCCTCCCTGGCTGCTGGCTGAGCTAGGGCCTAGCCTTGAGCAG
TGTTGCCTCATCCAGAAGAAAGCCAGTCTCCTCCCTATGATGCCAGTCCCTGCGTTCCCTGGCCCGAGCTGGTCTGGGGCCATTAGGCAG
CCTAATTAATGCTGGAGGCTGAGCCAAGTACAGGACACCCCCAGCCTGCAGCCCTTGCCCAGGGCACTTGGAGCACACGCAGCCATAGCA
AGTGCCTGTGTCCCTGTCCTTCAGGCCCATCAGTCCTGGGGCTTTTTCTTTATCACCCTCAGTCTTAATCCATCCACCAGAGTCTAGAAG
GCCAGACGGGCCCCGCATCTGTGATGAGAATGTAAATGTGCCAGTGTGGAGTGGCCACGTGTGTGTGCCAGTATATGGCCCTGGCTCTGC
ATTGGACCTGCTATGAGGCTTTGGAGGAATCCCTCACCCTCTCTGGGCCTCAGTTTCCCCTTCAAAAAATGAATAAGTCGGACTTATTAA
CTCTGAGTGCCTTGCCAGCACTAACATTCTAGAGTATTCCAGGTGGTTGCACATTTGTCCAGATGAAGCAAGGCCATATACCCTAAACTT
CCATCCTGGGGGTCAGCTGGGCTCCTGGGAGATTCCAGATCACACATCACACTCTGGGGACTCAGGAACCATGCCCCTTCCCCAGGCCCC
CAGCAAGTCTCAAGAACACAGCTGCACAGGCCTTGACTTAGAGTGACAGCCGGTGTCCTGGAAAGCCCCCAGCAGCTGCCCCAGGGACAT
GGGAAGACCACGGGACCTCTTTCACTACCCACGATGACCTCCGGGGGTATCCTGGGCAAAAGGGACAAAGAGGGCAAATGAGATCACCTC
CTGCAGCCCACCACTCCAGCACCTGTGCCGAGGTCTGCGTCGAAGACAGAATGGACAGTGAGGACAGTTATGTCTTGTAAAAGACAAGAA
GCTTCAGATGGGTACCCCAAGAAGGATGTGAGAGGTGGGCGCTTTGGAGGTTTGCCCCTCACCCACCAGCTGCCCCATCCCTGAGGCAGC
GCTCCATGGGGGTATGGTTTTGTCACTGCCCAGACCTAGCAGTGACATCTCATTGTCCCCAGCCCAGTGGGCATTGGAGGTGCCAGGGGA
GTCAGGGTTGTAGCCAAGACGCCCCCGCACGGGGAGGGTTGGGAAGGGGGTGCAGGAAGCTCAACCCCTCTGGGCACCAACCCTGCATTG
CAGGTTGGCACCTTACTTCCCTGGGATCCCCAGAGTTGGTCCAAGGAGGGAGAGTGGGTTCTCAATACGGTACCAAAGATATAATCACCT
AGGTTTACAAATATTTTTAGGACTCACGTTAACTCACATTTATACAGCAGAAATGCTATTTTGTATGCTGTTGAGTTTTTCTATCTGTGT

>13894_13894_1_CCDC6-PDGFRB_CCDC6_chr10_61564177_ENST00000263102_PDGFRB_chr5_149506177_ENST00000261799_length(amino acids)=989AA_BP=56
MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI
VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIQARAEQEEEFISNTLFKKIQALQKEKETLAVNYEKEEE
FLTNELSRKLMQLQHEKAELEQHLEQEQEFQVNKLMKKIKKLENDTISKQLTLEQLRREKIDLENTLEQEQEALVNRLWKRMDKLEAEKR
ILQEKLDQPVSAPPSPRDISMEIDSPENMMRHIRFLKNEVERLKKQLRAAQLQHSEKMAQYLEEERHMREENLRLQRKLQREMERREALC
RQLSESESSLEMDDERYFNEMSAQGLRPRTVSSPIPYTPSPSSSRPISPALPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWK
VIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSH
LGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDE
SVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEG
KLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPA
HASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEG

--------------------------------------------------------------
>13894_13894_2_CCDC6-PDGFRB_CCDC6_chr10_61564178_ENST00000263102_PDGFRB_chr5_149506178_ENST00000261799_length(transcript)=5005nt_BP=1337nt
AGTGCAATACTGCCCAAGCCCGGGCGGGGTCTCTGTTCTCTGGCAGAGGAGGTCCCTTGGCAGCGGGAAGCGCCCTCTCTTTCTCTCGCC
GCCGCTCCGAGTCTGCGCCCTGGTGCCAGGCGCTCAGCTCGGCGCTCCCCTGTGCTCGCCCGGCGCCCACTCATTCGCAGCCCGGCCTTC
GTCGCCGCCGCCTCCCTGCTGCTCCTCCTCCTTTCCCCAGCCCGCCGCGGCCATGGCGGACAGCGCCAGCGAGAGCGACACGGACGGGGC
GGGGGGCAACAGCAGCAGCTCGGCCGCCATGCAGTCGTCCTGCTCGTCGACCTCGGGCGGCGGCGGTGGCGGCGGGGGAGGCGGCGGCGG
TGGGAAGTCGGGGGGCATTGTCATCTCGCCGTTCCGCCTGGAGGAGCTCACCAACCGCCTGGCCTCGCTGCAGCAAGAGAACAAGGTGCT
GAAGATAGAGCTGGAGACCTACAAACTGAAGTGCAAGGCACTGCAGGAGGAGAACCGCGACCTGCGCAAAGCCAGCGTGACCATCCAAGC
CAGGGCTGAGCAGGAAGAAGAATTCATTAGTAACACTTTATTCAAGAAAATTCAGGCTTTGCAGAAGGAGAAAGAAACCCTTGCTGTAAA
TTATGAGAAAGAAGAAGAATTCCTCACTAATGAGCTCTCCAGAAAATTGATGCAGTTGCAGCATGAGAAAGCCGAACTAGAACAGCATCT
TGAACAAGAGCAGGAATTTCAGGTCAACAAACTGATGAAGAAAATTAAAAAACTGGAGAATGACACCATTTCTAAGCAACTTACATTAGA
ACAGTTGAGACGGGAGAAGATTGACCTTGAAAATACATTGGAACAAGAACAAGAAGCACTAGTTAATCGCCTCTGGAAAAGGATGGATAA
GCTTGAAGCTGAAAAGCGAATCCTGCAGGAAAAATTAGACCAGCCCGTCTCTGCTCCACCATCGCCTAGAGATATCTCCATGGAGATTGA
TTCTCCAGAAAATATGATGCGTCACATCAGGTTTTTAAAGAATGAAGTGGAACGGCTGAAGAAGCAACTGAGAGCTGCTCAGTTACAGCA
TTCAGAGAAAATGGCACAGTATCTGGAGGAGGAACGTCACATGAGAGAAGAGAACTTGAGGCTCCAGAGGAAGCTGCAGAGGGAGATGGA
GAGAAGAGAAGCCCTCTGTCGACAGCTCTCCGAGAGTGAGTCCAGCTTAGAAATGGACGACGAAAGGTATTTTAATGAGATGTCTGCACA
AGGATTAAGACCTCGCACTGTGTCCAGCCCGATCCCTTACACACCTTCTCCGAGTTCAAGCAGGCCTATATCACCTGCCTTGCCCTTTAA
GGTGGTGGTGATCTCAGCCATCCTGGCCCTGGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCACG
TTACGAGATCCGATGGAAGGTGATTGAGTCTGTGAGCTCTGACGGCCATGAGTACATCTACGTGGACCCCATGCAGCTGCCCTATGACTC
CACGTGGGAGCTGCCGCGGGACCAGCTTGTGCTGGGACGCACCCTCGGCTCTGGGGCCTTTGGGCAGGTGGTGGAGGCCACGGCTCATGG
CCTGAGCCATTCTCAGGCCACGATGAAAGTGGCCGTCAAGATGCTTAAATCCACAGCCCGCAGCAGTGAGAAGCAAGCCCTTATGTCGGA
GCTGAAGATCATGAGTCACCTTGGGCCCCACCTGAACGTGGTCAACCTGTTGGGGGCCTGCACCAAAGGAGGACCCATCTATATCATCAC
TGAGTACTGCCGCTACGGAGACCTGGTGGACTACCTGCACCGCAACAAACACACCTTCCTGCAGCACCACTCCGACAAGCGCCGCCCGCC
CAGCGCGGAGCTCTACAGCAATGCTCTGCCCGTTGGGCTCCCCCTGCCCAGCCATGTGTCCTTGACCGGGGAGAGCGACGGTGGCTACAT
GGACATGAGCAAGGACGAGTCGGTGGACTATGTGCCCATGCTGGACATGAAAGGAGACGTCAAATATGCAGACATCGAGTCCTCCAACTA
CATGGCCCCTTACGATAACTACGTTCCCTCTGCCCCTGAGAGGACCTGCCGAGCAACTTTGATCAACGAGTCTCCAGTGCTAAGCTACAT
GGACCTCGTGGGCTTCAGCTACCAGGTGGCCAATGGCATGGAGTTTCTGGCCTCCAAGAACTGCGTCCACAGAGACCTGGCGGCTAGGAA
CGTGCTCATCTGTGAAGGCAAGCTGGTCAAGATCTGTGACTTTGGCCTGGCTCGAGACATCATGCGGGACTCGAATTACATCTCCAAAGG
CAGCACCTTTTTGCCTTTAAAGTGGATGGCTCCGGAGAGCATCTTCAACAGCCTCTACACCACCCTGAGCGACGTGTGGTCCTTCGGGAT
CCTGCTCTGGGAGATCTTCACCTTGGGTGGCACCCCTTACCCAGAGCTGCCCATGAACGAGCAGTTCTACAATGCCATCAAACGGGGTTA
CCGCATGGCCCAGCCTGCCCATGCCTCCGACGAGATCTATGAGATCATGCAGAAGTGCTGGGAAGAGAAGTTTGAGATTCGGCCCCCCTT
CTCCCAGCTGGTGCTGCTTCTCGAGAGACTGTTGGGCGAAGGTTACAAAAAGAAGTACCAGCAGGTGGATGAGGAGTTTCTGAGGAGTGA
CCACCCAGCCATCCTTCGGTCCCAGGCCCGCTTGCCTGGGTTCCATGGCCTCCGATCTCCCCTGGACACCAGCTCCGTCCTCTATACTGC
CGTGCAGCCCAATGAGGGTGACAACGACTATATCATCCCCCTGCCTGACCCCAAACCCGAGGTTGCTGACGAGGGCCCACTGGAGGGTTC
CCCCAGCCTAGCCAGCTCCACCCTGAATGAAGTCAACACCTCCTCAACCATCTCCTGTGACAGCCCCCTGGAGCCCCAGGACGAACCAGA
GCCAGAGCCCCAGCTTGAGCTCCAGGTGGAGCCGGAGCCAGAGCTGGAACAGTTGCCGGATTCGGGGTGCCCTGCGCCTCGGGCGGAAGC
AGAGGATAGCTTCCTGTAGGGGGCTGGCCCCTACCCTGCCCTGCCTGAAGCTCCCCCCCTGCCAGCACCCAGCATCTCCTGGCCTGGCCT
GACCGGGCTTCCTGTCAGCCAGGCTGCCCTTATCAGCTGTCCCCTTCTGGAAGCTTTCTGCTCCTGACGTGTTGTGCCCCAAACCCTGGG
GCTGGCTTAGGAGGCAAGAAAACTGCAGGGGCCGTGACCAGCCCTCTGCCTCCAGGGAGGCCAACTGACTCTGAGCCAGGGTTCCCCCAG
GGAACTCAGTTTTCCCATATGTAAAATGGGAAAGTTAGGCTTGATGACCCAGAATCTAGGATTCTCTCCCTGGCTGACAGGTGGGGAGAC
CGAATCCCTCCCTGGGAAGATTCTTGGAGTTACTGAGGTGGTAAATTAACTTTTTTCTGTTCAGCCAGCTACCCCTCAAGGAATCATAGC
TCTCTCCTCGCACTTTTATCCACCCAGGAGCTAGGGAAGAGACCCTAGCCTCCCTGGCTGCTGGCTGAGCTAGGGCCTAGCCTTGAGCAG
TGTTGCCTCATCCAGAAGAAAGCCAGTCTCCTCCCTATGATGCCAGTCCCTGCGTTCCCTGGCCCGAGCTGGTCTGGGGCCATTAGGCAG
CCTAATTAATGCTGGAGGCTGAGCCAAGTACAGGACACCCCCAGCCTGCAGCCCTTGCCCAGGGCACTTGGAGCACACGCAGCCATAGCA
AGTGCCTGTGTCCCTGTCCTTCAGGCCCATCAGTCCTGGGGCTTTTTCTTTATCACCCTCAGTCTTAATCCATCCACCAGAGTCTAGAAG
GCCAGACGGGCCCCGCATCTGTGATGAGAATGTAAATGTGCCAGTGTGGAGTGGCCACGTGTGTGTGCCAGTATATGGCCCTGGCTCTGC
ATTGGACCTGCTATGAGGCTTTGGAGGAATCCCTCACCCTCTCTGGGCCTCAGTTTCCCCTTCAAAAAATGAATAAGTCGGACTTATTAA
CTCTGAGTGCCTTGCCAGCACTAACATTCTAGAGTATTCCAGGTGGTTGCACATTTGTCCAGATGAAGCAAGGCCATATACCCTAAACTT
CCATCCTGGGGGTCAGCTGGGCTCCTGGGAGATTCCAGATCACACATCACACTCTGGGGACTCAGGAACCATGCCCCTTCCCCAGGCCCC
CAGCAAGTCTCAAGAACACAGCTGCACAGGCCTTGACTTAGAGTGACAGCCGGTGTCCTGGAAAGCCCCCAGCAGCTGCCCCAGGGACAT
GGGAAGACCACGGGACCTCTTTCACTACCCACGATGACCTCCGGGGGTATCCTGGGCAAAAGGGACAAAGAGGGCAAATGAGATCACCTC
CTGCAGCCCACCACTCCAGCACCTGTGCCGAGGTCTGCGTCGAAGACAGAATGGACAGTGAGGACAGTTATGTCTTGTAAAAGACAAGAA
GCTTCAGATGGGTACCCCAAGAAGGATGTGAGAGGTGGGCGCTTTGGAGGTTTGCCCCTCACCCACCAGCTGCCCCATCCCTGAGGCAGC
GCTCCATGGGGGTATGGTTTTGTCACTGCCCAGACCTAGCAGTGACATCTCATTGTCCCCAGCCCAGTGGGCATTGGAGGTGCCAGGGGA
GTCAGGGTTGTAGCCAAGACGCCCCCGCACGGGGAGGGTTGGGAAGGGGGTGCAGGAAGCTCAACCCCTCTGGGCACCAACCCTGCATTG
CAGGTTGGCACCTTACTTCCCTGGGATCCCCAGAGTTGGTCCAAGGAGGGAGAGTGGGTTCTCAATACGGTACCAAAGATATAATCACCT
AGGTTTACAAATATTTTTAGGACTCACGTTAACTCACATTTATACAGCAGAAATGCTATTTTGTATGCTGTTGAGTTTTTCTATCTGTGT

>13894_13894_2_CCDC6-PDGFRB_CCDC6_chr10_61564178_ENST00000263102_PDGFRB_chr5_149506178_ENST00000261799_length(amino acids)=989AA_BP=56
MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI
VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIQARAEQEEEFISNTLFKKIQALQKEKETLAVNYEKEEE
FLTNELSRKLMQLQHEKAELEQHLEQEQEFQVNKLMKKIKKLENDTISKQLTLEQLRREKIDLENTLEQEQEALVNRLWKRMDKLEAEKR
ILQEKLDQPVSAPPSPRDISMEIDSPENMMRHIRFLKNEVERLKKQLRAAQLQHSEKMAQYLEEERHMREENLRLQRKLQREMERREALC
RQLSESESSLEMDDERYFNEMSAQGLRPRTVSSPIPYTPSPSSSRPISPALPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWK
VIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSH
LGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDE
SVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEG
KLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPA
HASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEG

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for CCDC6-PDGFRB

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for CCDC6-PDGFRB

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner	Gene	UniProtAcc	DrugBank ID	Drug name	Drug activity	Drug type	Drug status
Tgene	PDGFRB	P09619	DB00619	Imatinib	Antagonist	Small molecule	Approved
Tgene	PDGFRB	P09619	DB00619	Imatinib	Antagonist	Small molecule	Approved
Tgene	PDGFRB	P09619	DB00619	Imatinib	Antagonist	Small molecule	Approved
Tgene	PDGFRB	P09619	DB06589	Pazopanib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB06589	Pazopanib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB06589	Pazopanib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB08896	Regorafenib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB08896	Regorafenib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB08896	Regorafenib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB09079	Nintedanib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB09079	Nintedanib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB09079	Nintedanib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB10770	Foreskin fibroblast (neonatal)	Agonist	Biotech	Approved
Tgene	PDGFRB	P09619	DB10770	Foreskin fibroblast (neonatal)	Agonist	Biotech	Approved
Tgene	PDGFRB	P09619	DB10770	Foreskin fibroblast (neonatal)	Agonist	Biotech	Approved
Tgene	PDGFRB	P09619	DB14840	Ripretinib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB14840	Ripretinib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB14840	Ripretinib	Inhibitor	Small molecule	Approved
Tgene	PDGFRB	P09619	DB00102	Becaplermin		Biotech	Approved\|Investigational
Tgene	PDGFRB	P09619	DB00102	Becaplermin		Biotech	Approved\|Investigational
Tgene	PDGFRB	P09619	DB00102	Becaplermin		Biotech	Approved\|Investigational
Tgene	PDGFRB	P09619	DB00398	Sorafenib	Antagonist	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB00398	Sorafenib	Antagonist	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB00398	Sorafenib	Antagonist	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB01254	Dasatinib	Antagonist	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB01254	Dasatinib	Antagonist	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB01254	Dasatinib	Antagonist	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB01268	Sunitinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB01268	Sunitinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB01268	Sunitinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB06595	Midostaurin	Antagonist\|Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB06595	Midostaurin	Antagonist\|Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB06595	Midostaurin	Antagonist\|Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12147	Erdafitinib	Substrate	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12147	Erdafitinib	Substrate	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12147	Erdafitinib	Substrate	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12978	Pexidartinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12978	Pexidartinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB12978	Pexidartinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB15822	Pralsetinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB15822	Pralsetinib	Inhibitor	Small molecule	Approved\|Investigational
Tgene	PDGFRB	P09619	DB15822	Pralsetinib	Inhibitor	Small molecule	Approved\|Investigational

Top

Related Diseases for CCDC6-PDGFRB

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	CCDC6	C0238463	Papillary thyroid carcinoma	2	CTD_human;ORPHANET
Hgene	CCDC6	C3501843	Nonmedullary Thyroid Carcinoma	1	CTD_human
Hgene	CCDC6	C3501844	Familial Nonmedullary Thyroid Cancer	1	CTD_human
Tgene		C3554321	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 4	6	CTD_human;GENOMICS_ENGLAND;UNIPROT
Tgene		C0393590	Fahr's syndrome (disorder)	3	GENOMICS_ENGLAND;ORPHANET
Tgene		C4225270	Kosaki overgrowth syndrome	3	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Tgene		C4551572	MYOFIBROMATOSIS, INFANTILE, 1	3	GENOMICS_ENGLAND;UNIPROT
Tgene		C0013421	Dystonia	2	GENOMICS_ENGLAND
Tgene		C0023480	Leukemia, Myelomonocytic, Chronic	2	ORPHANET
Tgene		C0023893	Liver Cirrhosis, Experimental	2	CTD_human
Tgene		C0036341	Schizophrenia	2	PSYGENET
Tgene		C0432284	Infantile myofibromatosis	2	CTD_human;GENOMICS_ENGLAND;ORPHANET
Tgene		C0004782	Basal Ganglia Diseases	1	CTD_human
Tgene		C0006663	Calcinosis	1	CTD_human
Tgene		C0015371	Extrapyramidal Disorders	1	CTD_human
Tgene		C0036337	Schizoaffective Disorder	1	PSYGENET
Tgene		C0206648	Myofibromatosis	1	GENOMICS_ENGLAND
Tgene		C0263628	Tumoral calcinosis	1	CTD_human
Tgene		C0521174	Microcalcification	1	CTD_human
Tgene		C0750951	Lenticulostriate Disorders	1	CTD_human
Tgene		C1333046	Myeloproliferative Neoplasm, Unclassifiable	1	ORPHANET
Tgene		C1866182	Penttinen-Aula syndrome	1	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Tgene		C3472621	Myeloid neoplasm with beta-type platelet-derived growth factor receptor gene rearrangement	1	ORPHANET
Tgene		C3714756	Intellectual Disability	1	GENOMICS_ENGLAND

Fusion Gene Studies in Kim Lab

Fusion gene:CCDC6-PDGFRB (FusionGDB2 ID:HG8030TG5159)

Fusion Gene Summary for CCDC6-PDGFRB

Fusion Gene ORF analysis for CCDC6-PDGFRB

Fusion Genomic Features for CCDC6-PDGFRB

Fusion Protein Features for CCDC6-PDGFRB

Fusion Gene Sequence for CCDC6-PDGFRB

Fusion Gene PPI Analysis for CCDC6-PDGFRB

Related Drugs for CCDC6-PDGFRB

Related Diseases for CCDC6-PDGFRB

Fusion Gene Studies
in Kim Lab